Navigation Links
SNM's Clinical Trials Network expands European membership of PET biomarker manufacturers
Date:7/23/2009

Reston, Va.SNM's Clinical Trials Network today announced that several leading commercial providers of PET radiopharmaceuticals in Europe have registered their manufacturing sites with the network. SNM's Clinical Trials Network is an initiative designed to address the need for streamlined drug discovery through the integration of imaging biomarkers into multi-center clinical trials.

According to Michael M. Graham, M.D., Ph.D., SNM President and co-chair of the Clinical Trials Network, "SNM is very pleased to have the support of Advanced Accelerator Applications, Erigal Limited and IBA Molecular. Their participation in the network will afford European clinical trial sites the option to obtain investigational imaging agents like FLT from a commercial provider instead of having to produce it themselves." These commercial manufacturers represent 27 PET manufacturing sites in Europe.

The SNM Clinical Trials Network has received investigational new drug (IND) status for the use of FLT in multicenter studies. The goal of the network is to receive multicenter IND status for additional imaging biomarkers over time. Each imaging site that participates in a study using an SNM multicenter IND will need to demonstrate that the biomarker for the study is manufactured in a manner consistent with FDA standards. Now, in place of submitting detailed information about in-house production methods, sites will have the option to purchase investigational biomarkers from a commercial manufacturer with a drug master file (DMF) on file with the FDA. Advanced Accelerator Applications, Erigal Limited and IBA Molecular have all expressed interest in participating in future multicenter clinical trials under SNM INDs. Participation in any specific trial will require that these manufacturers have chemistry, manufacturing and control (CMC) information on file with the FDA for the investigational imaging biomarker being used in that trial.

"We hope that having commercial PET radiopharmaceutical producers supply investigational agents will further improve the level of standardization in imaging biomarker production. But this in no way reduces the need for single site produced biomarkers. We need both," said Dr. Graham.

Having commercial availability of IND PET drugs for use in clinical trials for future therapeutic agents will also greatly enhance the number of sites that have access to biomarkers like FLT and may increase the number of sites able to participate in these studies. SNM hopes that increased availability of sites to support clinical trials work will help drug developers better match imaging sites with targeted patient populations and may also speed the time to completion of trials by including more sites in each clinical trial.

There are currently 201 manufacturing sites registered with the network worldwide, with 23% located in European regions. SNM is pleased to have the support of all major U.S. multi-site PET manufacturers in the network registry as well, including Cardinal Health, IBA Molecular and PETNet Solutions.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie ... members, friends... and yourself and save. For a limited time only (offer expires May ... when buying more than one, by using the promo code "Memorial" at checkout. The ...
(Date:5/25/2016)... ... 25, 2016 , ... “We are very pleased to welcome ... “Brad brings significant experience advising healthcare provider clients throughout the country. As the ... of MACRA, we believe that continuing to add professionals with deep experience from ...
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity Recovery, a holistic ... highlighting one of the many supplemental program options offered at their rehabilitation facility, ... th Degree Black Belt in the Shorin-ryu style of Karate that originated in ...
(Date:5/25/2016)... CA (PRWEB) , ... May 25, 2016 , ... One ... and potential patients, according to an article published May 13th on Vanity ... are comfortable with having snippets of their procedures broadcast to more than 800,000 Snapchat ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... announces that Lake City Bank has selected IFN as a fiber transport provider. ... resulting in increased efficiencies and reduced costs. , “IFN provides fiber ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/23/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... programs. The hands-on learning experience is a 12-week summer ... Fellowship and Internship programs bring ... and interns are provided optional housing free of charge ... at the Riverfront Residence Hall to foster communication and ...
(Date:5/23/2016)... Non-invasive diagnostic test realizes the potential of ... be presented at Yissum’s booth, at IATI-BIOMED 2016 conference  ... the Hebrew University of Jerusalem announced today it ... MKI, the technology investment arm of Morris Kahn , ... early detection of multiple diseases by analyzing circulating DNA ...
Breaking Medicine Technology: